お知らせ • Nov 16
Grapefruit USA, Inc. announced delayed 10-Q filing On 11/15/2022, Grapefruit USA, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC. お知らせ • Aug 17
Grapefruit USA, Inc. announced delayed 10-Q filing On 08/16/2022, Grapefruit USA, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC. お知らせ • May 18
Grapefruit USA, Inc. announced delayed 10-Q filing On 05/17/2022, Grapefruit USA, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC. お知らせ • Apr 20
Health Canada Approves NNCP for Grapefruit USA, Inc. Hourglass Time Release THC+CBD Delivery Cream Grapefruit USA, Inc. announced that its Notice of New Cannabis Product (“NNCP”), filed with Health Canada on Jan. 11, 2022, was approved by Health Canada on March 21, 2022, under NNCP ID No. NP-V2EHUWO907. As a result, Grapefruit is now authorized to sell its patented Hourglass™ Time Release THC+CBD infused Topical Delivery Cream to licensed retail outlets throughout Canada. Approval of Grapefruit’s NNCP was a mandatory prerequisite to the launch of Grapefruit’s Hourglass technology-based products in Canada. As a result of the Health Canada Hourglass™ NNCP approval, Grapefruit can sell Hourglass THC-infused products throughout both California and Canada, which have a combined population in excess of 75 million people. Grapefruit believes its Hourglass™ THC/CBD delivery cream is a truly disruptive technology that will fundamentally change the way humans safely ingest THC, CBD and other cannabinoids to enjoy their unique holistic benefits without exposure to the dangers of smoking and/or orally ingesting THC, CBD and other cannabinoids. A simple application of Grapefruit’s Hourglass™ THC/CBD/cannabinoid cream is all that is needed for Hourglass users to obtain the full-body entourage effects and related benefits of THC, CBD and a wide array of other beneficial cannabinoids. The disruptive Hourglass technology enables users, for the first time, to effectively use a variety of cannabis products in a healthy fashion. Simply put, Hourglass-based products work without the health risks from smoking or orally ingesting THC and CBD. お知らせ • Apr 03
Grapefruit USA, Inc. announced delayed annual 10-K filing On 04/01/2022, Grapefruit USA, Inc. announced that they will be unable to file their next 10-K by the deadline required by the SEC. お知らせ • Mar 29
Grapefruit USA, Inc. (OTCPK:GPFT) signed a Memorandum of Understanding to acquire Substantially All Assets of Diagnostic Lab Corporation, Inc. from Diagnostic Lab Corporation, Inc. Grapefruit USA, Inc. (OTCPK:GPFT) signed a Memorandum of Understanding to acquire Substantially All Assets of Diagnostic Lab Corporation, Inc. from Diagnostic Lab Corporation, Inc. on March 22, 2022. Grapefruit USA, Inc. (OTCPK:GPFT) will issue a to be agreed upon number of its common shares in consideration of the Acquisition. The transaction is subject to Due Diligence Review by Diagnostic Lab Corporation, Inc., signing of a binding Letter of Intent and a Definitive Agreement. The parties will sign a binding Letter of Intent on or before April15, 2022 and will close the transaction on or before September 1, 2022. お知らせ • Mar 05
Grapefruit USA, Inc. Updates on Hourglass Health Canada NNCP Submission Grapefruit USA, Inc. announced Notice of New Cannabis Product filed with Health Canada for its patented Hourglass™ Time Release THC+CBD infused Topical Delivery Cream. Approval of the NNCP by Health Canada will enable Grapefruit to sell its patented Hourglass™ Time Release THC+CBD infused Topical Delivery Cream to licensed retail outlets throughout Canada. Health Canada is the department of the federal government of Canada responsible for national health policy. It approves and oversees the production of all cannabis products and is the licensing authority for all companies involved in the cannabis industry. Health Canada requires all cannabis products meet federal regulatory requirements before they can be sold in Canada. Under Canada’s Federal Cannabis Regulatory scheme, Health Canada must be notified of a company’s intent to sell a cannabis product that has not previously been sold in the country. Approval of the NNCP is a mandatory prerequisite to the launch of Grapefruit’s Hourglass technology-based products in Canada. On Feb. 18, 2022, Grapefruit received an inquiry from Health Canada about the composition of specific Hourglass ingredients. Grapefruit’s timely response to the inquiry was promptly accepted by Health Canada. Grapefruit believes its Hourglass™ THC/CBD delivery cream system is a truly disruptive technology which has fundamentally changed the way humans safely ingest THC, CBD and other cannabinoids to enjoy their unique holistic benefits without the dangers of smoking and/or oral ingestion. A simple application of Grapefruit’s Hourglass™ THC/CBD/cannabinoid cream is all that is needed for Hourglass users to obtain the full-body entourage effects and related benefits of THC, CBD and a wide array of other beneficial cannabinoids. お知らせ • Feb 24
Grapefruit Usa, Inc. Announces CEO Bradley J. Yourist Has Been Elected to the Coachillin’ Industrial Cultivation and Ancillary Canna-Business Park’S Property Owners Association Board of Directors Grapefruit USA, Inc. announced that its Chief Executive Officer Bradley J. Yourist has been elected to the Coachillin’ Industrial Cultivation and Ancillary Canna-Business Park’s Property Owners Association Board of Directors for a one-year term, effective immediately. お知らせ • Dec 07
Grapefruit USA Announce Official Launch of Patented Time-Release, Hemp-Based CBD Topical Cream with Boosted Bioavailability, Made Possible by Its Proprietary Hourglass™ Technology Grapefruit USA, Inc. announced the official launch of the world’s first patented time-release, hemp-based CBD topical cream with boosted bioavailability, made possible by its proprietary Hourglass™ technology. Hourglass™ is a unique method for staggered and discreet topical delivery of CBD. The brand-new technology, developed by Grapefruit, leverages a proprietary process that involves the grinding of CBD into nano sized particles, substantially smaller than the width of a human hair, which allows for significantly higher bioavailability and absorption. The nano-particle technology enables anyone who wants to enjoy the incredible holistic benefits of CBD to do so, both immediately and over a sustained period of up to 8-10 hours, in a discreet and convenient manner. The micro-sized vessels called “Z-Pods™”, lodge deep into human pores and follicles, persisting there, before slowly releasing CBD over an extended time period, forming what Grapefruit has dubbed the “Patchless-Patch™” system. お知らせ • Aug 18
Grapefruit USA, Inc. announced delayed 10-Q filing On 08/17/2021, Grapefruit USA, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC. お知らせ • Jun 15
Grapefruit Usa, Inc. Expands its Hemp Based CBD Products with a New USDA Certified Organic CBD Pet Tincture Grapefruit USA, Inc. (‘GPFT,’ ‘Grapefruit’ or the ‘Company’) announced that it is expanding its hemp-based cannabidiol (‘CBD’) product line with a new U.S. Department of Agriculture (‘USDA’) certified CBD pet tincture targeting two of the most common dog and cat ailments – anxiety and joint pain. Grapefruit’s new Pet 300 mg CBD hemp-based tincture is derived from USDA Certified Organic hemp, grown only in the United States. The pet CBD industry has experienced significant growth over the last several years, with an expected market valuation of over $1.7 billion by 2025, according to the Brightfield Group. Overall pet ownership is also increasing, due partly to the pandemic, with more than half of U.S. households having a pet dog or cat and 64% of CBD consumers are specifically buying CBD products for their pets because of the holistic benefits they provide. The global CBD pet market size was valued at USD 27.7 million in 2019 and is expected to grow at a compound annual growth rate (CAGR) of 40.3% from 2020 to 2027. The perceived benefits of cannabis, high awareness among pet owners, and consumers’ preference for natural pet supplements have led to an upsurge in the growth of this market. お知らせ • May 19
Grapefruit USA, Inc. announced delayed 10-Q filing On 05/18/2021, Grapefruit USA, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC. お知らせ • May 11
Grapefruit USA, Inc. Launches New Affiliate Program in Conjunction with New E-Commerce Store Grapefruit USA, Inc. announced its new Affiliate Program which will complement its new E-Commerce Store. The new Affiliate Program is designed to facilitate the ability of approved and authorized third party resellers with existing online retail platforms to market and sell Grapefruit’s THC-free hemp derived CBD Hourglass powered products. お知らせ • Apr 03
Grapefruit USA, Inc. announced delayed annual 10-K filing On 04/01/2021, Grapefruit USA, Inc. announced that they will be unable to file their next 10-K by the deadline required by the SEC. お知らせ • Mar 16
Grapefruit USA, Inc. Announces Hourglass™ Time Release THC+CBD Delivery Cream Now Available on Crown Genetics Mobile Retail Distribution Platform Grapefruit USA, Inc. announced that its patented, disruptive Hourglass™ time release THC+ Cannabinoid delivery cream and full spectrum RSO cannabis oil are now available for purchase on Crown Genetics’ (“Crown”) retail delivery online platform in California under the “Wellness” section. As a result, customers who live in Los Angeles County can have Hourglass delivered to their home or office via the Crown delivery distribution system. The public will also be able to buy Hourglass™, as well as Grapefruit’s full spectrum RSO oil, at any of the over 250 California licensed retail dispensaries serviced by the Crown distribution system as soon as these products are delivered and stocked in these retail outlets. Hourglass™ and the RSO are currently available for retail purchase at the Apothecary 420 Dispensary in Sherman Oaks, California. お知らせ • Mar 09
Grapefruit USA, Inc. Announces Resignation of John Hollister from the Board of Directors Grapefruit USA, Inc. announced that on February 26, 2021 John Hollister resigned from the Company's board of directors. Mr. Hollister's resignation was accepted by the Board. お知らせ • Mar 03
Grapefruit USA, Inc. Signs Memorandum of Understanding with Canadian Partner to Form New Joint Venture Corporation to Manufacture and Distribute its Patented, Disruptive Hourglass THC/ Cannabinoid Products Grapefruit USA, Inc. signed a memorandum of understanding (the MOU) with a Canadian Partner which sets forth the general terms of their agreement to form a new joint venture corporation to manufacture and distribute the company’s patented, disruptive Hourglass THC/cannabinoid products, throughout the Commonwealth of Canada including on Canadian First Nation Lands. Under the terms of the MOU, products to be sold in Canada shall be manufactured in Canada in licensed facilities, and in some cases under appropriate framework on Canadian First Nations Land under license from the company by the joint venture, with the provision of technical know-how, lab staff and the patented Z-Pod by the company and provision of compliant Canadian-made THC/CBD distillates and terpenes by the Canadian Partner. Subject to certain, yet to be negotiated issues the joint venture shall be managed jointly by the company and the Canadian Partner and joint venture profits will generally be split 50%/50%, subject to certain exceptions. The Canadian Partner shall have exclusive rights with respect to sales of Hourglass products in Health Canada Permitted retail locations, and in First Nation’s Lands, from the formation of the joint venture with exclusive rights with respect to sales of Hourglass products throughout Canada for 180 days while the parties negotiate in good faith to establish unit sales minimums to support exclusivity. お知らせ • Feb 23
Grapefruit USA, Inc. Secures Trademark Protection for the ‘Hourglass’ Name and Logo Grapefruit USA, Inc. announced that it has obtained California Trademark protection for Grapefruit’s patented disruptive Hourglass™ THC/Cannabinoid time-release delivery cream. The Hourglass™ name and logo are protected intellectual property rights of the Company which prevents all others operating in the Cannabis space from exploitation of such property. The Company also possesses common law, first-in-time, trademark protection to Hourglass™. The Company will obtain its Federal trademark protection when the Federal government legalizes cannabis, expected by many to be later this year.